Jacobson Pharma Corporation Limited (Stock Code: 02633) and JBM (Healthcare) Limited (Stock Code: 2161) have jointly announced the renewal of certain continuing connected transactions (the 2026 Framework Agreements). These agreements extend the existing 2023 Framework Agreements, which will expire on 31 March 2026, for a period of three years from 1 April 2026 to 31 March 2029.

Jacobson and JBM are considered connected persons under Chapter 14A of the Listing Rules because a common controlling shareholder holds approximately 70.25% of Jacobson and approximately 71.62% of JBM. As the highest relevant percentage ratios exceed 0.1% but remain below 5%, the renewed transactions are subject to reporting, announcement, and annual review requirements but exempt from circular and independent shareholders’ approval.

Under the 2026 Logistics Services Agreement, the Jacobson Group will continue providing logistics services to the JBM Group. Historical transaction amounts under the existing arrangement were approximately HK$4.08 million, HK$4.55 million, and HK$5.15 million for the respective past periods. The new annual caps for the years ending 31 March 2027, 2028, and 2029 are set at HK$8.00 million, HK$9.00 million, and HK$10.00 million.

Meanwhile, the 2026 Manufacturing Services Agreement covers manufacturing of selected generic drugs by the JBM Group for the Jacobson Group. Historical service fees paid were approximately HK$3.39 million, HK$4.19 million, and HK$2.00 million. The new annual caps are HK$7.00 million, HK$8.00 million, and HK$9.00 million for the same respective three-year period.

Both companies have stated that the agreements are based on normal commercial terms, reflecting costs plus specified profit margins. The boards of both Jacobson and JBM consider the terms fair and reasonable, serving the ordinary course of business and the interests of shareholders as a whole.